2023
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Gandhi R, Bedimo R, Hoy J, Landovitz R, Smith D, Eaton E, Lehmann C, Springer S, Sax P, Thompson M, Benson C, Buchbinder S, del Rio C, Eron J, Günthard H, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA 2023, 329: 63-84. PMID: 36454551, DOI: 10.1001/jama.2022.22246.Peer-Reviewed Original ResearchConceptsPrevention of HIVAntiretroviral therapySubstance use disordersAntiretroviral drugsUse disordersCertain antiretroviral medicationsDaily oral regimenInhibitor-containing regimensManagement of comorbiditiesMonkeypox virus infectionDiagnosis of HIVSARS-CoV-2 pandemicCare of peopleGlobal health emergencyInitial therapyOral regimenAdherence supportMetabolic complicationsPreexposure prophylaxisViral suppressionAntiretroviral medicationsOral medicationsHIV infectionLaboratory monitoringInjectable therapies
2022
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.Peer-Reviewed Original ResearchConceptsOpioid use disorderHigher pain interferenceMOUD retentionPain interferenceUse disordersOngoing prospective cohort studySevere opioid use disorderProspective cohort studyMultivariable logistic regressionCohort of adultsMethadone doseAnalgesic effectBuprenorphine doseCohort studyOpioid useResultsA totalHigher oddsMOUDAdjusted modelHigh doseLogistic regressionBuprenorphineMethadoneDoseDiscontinuation
2021
Feasibility of a community‐based delivery model for HIV pre‐exposure prophylaxis among bar patrons in rural South Africa
Grammatico MA, Moll AP, Choi K, Springer SA, Shenoi SV. Feasibility of a community‐based delivery model for HIV pre‐exposure prophylaxis among bar patrons in rural South Africa. Journal Of The International AIDS Society 2021, 24: e25848. PMID: 34826363, PMCID: PMC8625837, DOI: 10.1002/jia2.25848.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisAlcohol Use Disorders Identification TestLargest HIV epidemicCommunity-based delivery modelPrEP uptakeHIV testingOdds ratioOral tenofovir disoproxil fumarate/emtricitabineTenofovir disoproxil fumarate/emtricitabineRural South AfricaHazardous drinkingDisoproxil fumarate/emtricitabineHIV pre-exposure prophylaxisUptake of PrEPHIV care cascadeRapid HIV testingAdjusted odds ratioYoung menRural KwaZulu-Natal ProvinceAlcohol use disorderSexual risk behaviorsDisorders Identification TestBar patronsPrEP deliveryPrEP initiatorsIndividual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort
Fredericksen RJ, Whitney BM, Trejo E, Nance RM, Fitzsimmons E, Altice FL, Carrico AW, Cleland CM, Del Rio C, Duerr A, El-Sadr WM, Kahana S, Kuo I, Mayer K, Mehta S, Ouellet LJ, Quan VM, Rich J, Seal DW, Springer S, Taxman F, Wechsberg W, Crane HM, Delaney JAC. Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort. BMC Public Health 2021, 21: 2002. PMID: 34736425, PMCID: PMC8567631, DOI: 10.1186/s12889-021-12026-7.Peer-Reviewed Original ResearchConceptsLikelihood of CSRecent substance useHIV-negative partnersVaginal sexAnal sexSubstance useHIV-status unknown partnersMultivariable relative risk regressionExposure classificationType of sexHIV-negative adultsPooled effect estimatesPartner's HIV statusMulti-site cohortHigher likelihoodHeterosexual sexRelative risk regressionSingle substance usePoly-substance useHIV-negativeHIV statusRisk regressionPolysubstance useCannabis useSU exposureLong-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal Of Substance Use And Addiction Treatment 2021, 128: 108389. PMID: 33865691, PMCID: PMC8384640, DOI: 10.1016/j.jsat.2021.108389.Peer-Reviewed Original ResearchConceptsOpioid use disorderSelf-reported opioid useOpioid-positive urine samplesExtended-release buprenorphineExtended-release naltrexoneOpioid overdose eventsXR-NTXOpioid treatmentObservational cohortOpioid useUsual armCare outcomesUse disordersNoninferiority designOverdose eventsUrine samplesBuprenorphineTreatmentAdultsEnhanced treatmentNaltrexoneRCTsCohortU.S. localesTrialsDesign and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder
Seval N, Frank CA, Litwin AH, Roth P, Schade MA, Pavlicova M, Levin FR, Brady KT, Nunes EV, Springer SA. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemporary Clinical Trials 2021, 105: 106394. PMID: 33838307, PMCID: PMC8172465, DOI: 10.1016/j.cct.2021.106394.Peer-Reviewed Original ResearchConceptsOpioid use disorderInfectious disease treatmentUse disordersCo-occurring opioid use disorderTreatment of OUDLife-threatening infectious diseaseSubstantial healthcare utilizationProportion of patientsInfectious disease specialistsInjection drug usePrimary outcome measureIntegrated care modelDisease treatmentMulti-site trialInjectable buprenorphineOpioid useSecondary outcomesHealthcare utilizationInfection morbidityDisease specialistsMedication treatmentSerious infectionsMonthly formulationDrug overdoseID specialists
2020
Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.
Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.Peer-Reviewed Original ResearchConceptsHazardous alcohol useFormer injection drug useART receiptViral suppressionInjection drug useLow-middle income countriesAlcohol useAntiretroviral therapyMiddle-income countriesDrug useAlcohol Use Disorders Identification Test (AUDIT) scoresHIV viral suppressionAlcohol Use Disorders Identification TestDisorders Identification TestTherapy receiptHIV continuumMean ageHigh-income countriesCare outcomesLogistic regressionUpper middle-income countriesPLHIVDrugsIdentification TestHIV
2019
Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations
Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. BMC Infectious Diseases 2019, 19: 913. PMID: 31664910, PMCID: PMC6819597, DOI: 10.1186/s12879-019-4443-z.Peer-Reviewed Original ResearchConceptsViral loadART adherenceAdherence measuresSelf-reported antiretroviral therapy (ART) adherenceCriminal justice-involved populationsSelf-reported ART adherenceLogistic regressionSelf-reported health statusContinuum of HIVDetectable viral loadPlasma viral loadAIDS Research NetworkAntiretroviral therapy adherenceAssociation of adherenceHealth status levelsVisual analog scaleViral load dataMixed-effects logistic regressionMixed effects linear regressionEffects linear regressionJustice-involved populationsEffects logistic regressionVL outcomesCD4 countART dosesTreating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Use And Addiction Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist treatmentXR-NTX injectionXR-NTX treatmentXR-NTXUrine drug testingOpioid useExtended-release naltrexoneMonths of treatmentThree-month outcomeHealth-related qualityAdverse side effectsSymptoms of depressionOpioid dependenceAgonist treatmentLife scoresTreatment optionsIndependent factorsSide effectsUse disordersPeriod of observationDrug useStimulant useTreatment motivationDrug testing
2018
Brief Report
Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Trejo MEP, Matsuzaki M, Taxman FS, Chander G, Kuo I, Fredericksen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, Springer S, Chandler R, Kahana S, Crane HM. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 283-287. PMID: 30036277, PMCID: PMC6681811, DOI: 10.1097/qai.0000000000001803.Peer-Reviewed Original ResearchConceptsPHQ-9 scoresDepressive symptomsSubstance useATS useLower oddsMean decreaseAmphetamine-type substancesAIDS Research NetworkCocaine/crack useDepressive symptom scoresMental health disordersJoint longitudinal-survival modelCocaine/crackPoor outcomeSymptom scoresPHQ-9Health disordersIllicit opiatesSymptomsPLWHLongitudinal assessmentSite cohortSubstance use frequencyCrack useAbstinenceApproaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations
Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations. Drug And Alcohol Dependence 2018, 194: 59-68. PMID: 30412898, PMCID: PMC6312501, DOI: 10.1016/j.drugalcdep.2018.10.003.Peer-Reviewed Original ResearchExtended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomesPrevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision
Mbaba M, Brown SE, Wooditch A, Kiss M, Murphy A, Kumari S, Taxman F, Altice F, Lawson WB, Springer SA. Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision. Substance Use & Misuse 2018, 53: 1519-1528. PMID: 29333954, PMCID: PMC6432769, DOI: 10.1080/10826084.2017.1416400.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-9Mood disordersBipolar disorderOpioid usersAddiction Severity Index-LiteOpioid use treatmentCriminal justice supervisionOpioid-dependent individualsSelf-reported mood disordersOpioid-dependent populationsComprehensive psychiatric careAdverse health consequencesLarger parent studyLifetime suicide attemptsHigh rateQuestionnaire-9Positive screenJustice-involved individualsSevere depressionTreatment utilizationGeneral U.S.Psychiatric careControl trialParent studyPsychiatric disordersA qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine
Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, Springer SA. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 86: 86-93. PMID: 29415856, PMCID: PMC5808584, DOI: 10.1016/j.jsat.2018.01.003.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyXR-NTXExtended-release naltrexonePsychological supportOpioid use disorderHIV prevention effortsFocus groupsPerceptions of recoveryAgonist therapyOpioid withdrawalYoung PWIDOpioid antagonistPatient preferencesNew pharmacotherapiesPsychoactive medicationsInjection careerUse disordersFocus group transcriptsPWIDPrevention effortsNaltrexoneGroup transcriptsIndividual barriersTreatmentWithdrawal
2017
Cohort profile: seek, test, treat and retain United States criminal justice cohort
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, And Policy 2017, 12: 24. PMID: 28511680, PMCID: PMC5433052, DOI: 10.1186/s13011-017-0107-4.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsTreatment cascadeViral loadHIV RNA viral loadCD4 T-cell countRisk behaviorsSubstance useT-cell countsHepatitis C infectionRNA viral loadInjection drug useHealth Related QualityHIV treatment cascadeUnprotected sexual intercourseHealth care accessRecent polysubstance useC infectionViral suppressionHIV diagnosisHIV infectionMedian ageRelated qualityCriminal justice involvementART treatmentCohort membersExtended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexoneGender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium
Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium. AIDS And Behavior 2017, 21: 2945-2957. PMID: 28188460, PMCID: PMC5552433, DOI: 10.1007/s10461-017-1722-9.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsRisk behaviorsHIV risk reduction interventionsHIV-negative participantsHIV-positive womenHIV-positive menMultilevel mixed-effects logistic regression modelSero-discordant partnersMixed effects logistic regression modelsCondomless sexual intercourseRisk reduction interventionsLogistic regression modelsCJ populationsBehavior Assessment ToolHIV transmissionCriminal justice populationsHigher oddsHIVReduction interventionsSexual intercourseLarge-scale studiesBaseline dataInjection equipmentJustice populationsAssessment tool
2016
Co-calibration of two self-reported measures of adherence to antiretroviral therapy
Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care 2016, 29: 464-468. PMID: 27910703, PMCID: PMC5291764, DOI: 10.1080/09540121.2016.1263721.Peer-Reviewed Original ResearchConceptsVisual analog scaleAntiretroviral therapyAdherence measuresAIDS Clinical Trials Group questionnaireHigh-risk vulnerable populationsVulnerable populationsCare cohortAnalog scaleVAS scaleHIV StudyAdherence dataClinical successConsortium studyGroup questionnaireTherapyDosesSelf-report measuresAdherenceDeterminants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug And Alcohol Dependence 2016, 165: 213-220. PMID: 27370527, PMCID: PMC5094181, DOI: 10.1016/j.drugalcdep.2016.06.011.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentAdjusted odds ratioOpioid use disorderAgonist treatmentUse disordersSignificant adjusted odds ratiosMultivariable logistic regressionHIV-negative statusPatient-level interventionsOpioid-dependent peopleInjection frequencyHIV statusOdds ratioRecent overdoseIndependent factorsPWIDLogistic regressionPrevious imprisonmentHigher injection frequencySignificant correlatesPrior incarcerationFamily supportDisordersDrugsIntervention